Illumina (NASDAQ:ILMN) Stock Price Expected to Rise, Piper Sandler Analyst Says

Illumina (NASDAQ:ILMN) had its target price increased by research analysts at Piper Sandler from $170.00 to $200.00 in a report issued on Wednesday, MarketBeat.com reports. The firm presently has an “overweight” rating on the life sciences company’s stock. Piper Sandler’s price objective would indicate a potential upside of 13.75% from the stock’s previous close.

A number of other analysts also recently weighed in on ILMN. JPMorgan Chase & Co. upgraded Illumina from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $125.00 to $185.00 in a research report on Wednesday, June 10th. Weiss Ratings raised shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Barclays boosted their price objective on shares of Illumina from $122.00 to $145.00 and gave the stock an “underweight” rating in a report on Wednesday, June 24th. Royal Bank Of Canada assumed coverage on shares of Illumina in a research note on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price objective for the company. Finally, Wall Street Zen lowered shares of Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Eight investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $148.94.

Illumina Stock Performance

Illumina stock opened at $175.83 on Wednesday. Illumina has a fifty-two week low of $88.00 and a fifty-two week high of $182.84. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The stock has a market cap of $26.60 billion, a P/E ratio of 31.97, a price-to-earnings-growth ratio of 3.39 and a beta of 1.50. The firm’s fifty day moving average price is $151.42 and its 200-day moving average price is $138.36.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.10. The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities research analysts expect that Illumina will post 5.21 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CAO Scott D. Ericksen sold 1,500 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $150.10, for a total transaction of $225,150.00. Following the completion of the sale, the chief accounting officer directly owned 14,946 shares in the company, valued at $2,243,394.60. This represents a 9.12% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 700 shares of the stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the sale, the senior vice president directly owned 15,056 shares of the company’s stock, valued at $2,093,386.24. The trade was a 4.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,003,769 shares of company stock valued at $155,710,908 over the last quarter. Company insiders own 2.90% of the company’s stock.

Institutional Trading of Illumina

A number of institutional investors have recently modified their holdings of the company. Elyxium Wealth LLC purchased a new position in Illumina during the 4th quarter valued at about $25,000. Creative Capital Management Investments LLC raised its position in Illumina by 160.0% during the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares during the last quarter. Board of the Pension Protection Fund purchased a new stake in Illumina in the 4th quarter worth approximately $26,000. TD Waterhouse Canada Inc. purchased a new stake in Illumina in the 4th quarter worth approximately $26,000. Finally, Laurel Wealth Advisors LLC bought a new stake in shares of Illumina in the 4th quarter worth approximately $26,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.